C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on August 2, 2022, regarding events that occurred on July 29, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol CCCC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors elected two new directors on July 29, 2022:
- Donna Grogan, M.D.: Elected as a Class II director, serving until the 2025 Annual Meeting of Stockholders.
- Laura Bessen, M.D.: Elected as a Class I director, serving until the 2024 Annual Meeting of Stockholders.
In connection with these elections, the Company granted each director stock options to purchase up to 41,200 shares of common stock under the 2020 Stock Option and Incentive Plan. The vesting schedule is as follows:
- One-third vests on the first anniversary of the grant date.
- The remainder vests quarterly over the subsequent two years.
- Vesting ceases if the director resigns or ceases to serve prior to a vesting date.
The Company also entered into standard indemnification agreements with both new directors.
Guidance, Outlook, and Risks
This filing does not provide financial guidance, management commentary on business outlook, or discuss specific risks or contingencies beyond the standard disclosure regarding the new director appointments. A press release announcing these elections was issued on August 2, 2022.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the impact of the 82,400 new option grants on potential dilution.
- Review the Company's 2020 Stock Option and Incentive Plan to confirm the availability of shares for these grants.
- Confirm the professional backgrounds of Dr. Grogan and Dr. Bessen to assess their strategic value to the Board.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.